Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Gossamer Bio Inc. (GOSS) Prices 9.433M Share Common Offering at $13.25/Sh; Announces Pricing of $200M Convertible Senior Notes Due 2027
May 18, 2020 5:44 PM EDT
After-Hours Stock Movers:
Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.
Gamida Cell... More
May 18, 2020 4:04 PM EDT
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the notes) in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.
Gossamer also expects to grant the underwriters of the common stock offering a 30-day... More
